{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["EGFRI Induced Acneiform Lesions"],"disease":["Egfri Induced Acneiform Lesions"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2367764"],"location":["United States","Israel"],"study_start_month":["4"],"keyword":["EGFRI, Acneiform, Acneiform lesions, Acneiform rash, EGFRI induced skin toxicities","LUT014"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC","description":"The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions","dates":{"creation":"2021-04-15"},"accession":"2367764","cross_references":{"ClinicalTrials___gov":["NCT04759664"]}}